首页 | 本学科首页   官方微博 | 高级检索  
     


Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
Authors:Ofer Margalit,Einat Shacham‐  Shmueli,Yu‐  Xiao Yang,Yaacov R. Lawerence,Idan Levy,Kim A. Reiss,Talia Golan,Naama Halpern,Dan Aderka,Bruce Giantonio,Ronac Mamtani,Ben Boursi
Affiliation:1. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel

Tel-Aviv University, Tel-Aviv, Israel

Contributed equally.;2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;3. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel

Tel-Aviv University, Tel-Aviv, Israel

Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA;4. Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel;5. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA;6. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel

Tel-Aviv University, Tel-Aviv, Israel;7. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA;8. Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;9. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel

Abstract:
BackgroundCurrent guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically staged patients identifies more advanced locoregional disease requiring adjuvant treatment. Therefore, identifying these patients prior to surgical intervention is critical to ensure employment of the appropriate treatment paradigm. The aim of the current study was to define patient characteristics associated with clinical understaging in early gastric cancer.MethodsUsing the National Cancer Database (2004–2014) we identified 3,892 individuals with clinical T1N0 gastric adenocarcinoma who underwent upfront definitive surgery, had negative surgical margins, and did not receive preoperative chemotherapy or radiotherapy. Patient characteristics were compared between those with pathologic stage T1N0 disease and those who were upstaged upon surgery.ResultsTwenty‐seven percent of clinical T1N0 gastric adenocarcinomas had a change in stage because of pathologically defined ≥T2 disease or positive lymph nodes. Individuals who were upstaged had a higher tumor grade compared with those with pathologic stage T1N0 disease. Specifically, 41.9% (530/1,264) of individuals with a poorly differentiated tumor were upstaged, compared with only 10.7% (70/656) with a well‐differentiated tumor. Approximately 75% of cases involved upstaging because of T misclassification. The highest percentage of upstaging was shown for tumors located at the fundus and body of the stomach.ConclusionUpstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy.Implications for PracticeUpstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy.
Keywords:Gastric adenocarcinoma   Clinical T1N0   Poor differentiation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号